PF-562271 HCl: Precision FAK/Pyk2 Inhibition in Cancer Research

Principle and Setup: Leveraging a Selective ATP-Competitive FAK Inhibitor

PF-562271 HCl is a potent, reversible, and ATP-competitive inhibitor targeting focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2). FAK is a non-receptor tyrosine kinase central to cell adhesion, migration, and survival—processes fundamentally linked to tumor progression and metastasis. Pyk2, a homolog sharing 48% amino acid identity with FAK, is similarly implicated in oncogenic signaling pathways. The nanomolar potency of PF-562271 HCl (IC₅₀ = 1.5 nM for FAK; 14 nM for Pyk2) and its selectivity—approximately 10-fold for FAK over Pyk2, and over 100-fold against other kinases (except some CDKs)—enable precise dissection of the focal adhesion kinase signaling pathway in cancer research models.

Supplied as a solid by APExBIO, this compound is highly soluble in DMSO (≥26.35 mg/mL with gentle warming) but insoluble in water and ethanol. For best results, store at -20°C and use solutions promptly to maintain activity and reproducibility.

Step-by-Step Experimental Workflow: Enhancing FAK/Pyk2 Inhibition Protocols

1. Preparation and Handling

• Stock Solution Preparation: Dissolve PF-562271 HCl in DMSO to a concentration of 10 mM or higher. Gently warm (37°C) if needed for complete dissolution.
• Aliquot and Storage: Aliquot stock solutions to minimize freeze-thaw cycles. Avoid long-term storage of solutions; prepare working aliquots fresh before each experiment.
• Working Concentrations: Typical in vitro concentrations range from 10 nM to 1 μM, depending on cell type and assay sensitivity. For in vivo studies, dose adjustments should consider pharmacokinetics and bioavailability, referencing published tumor model data (e.g., EC₅₀ = 93 ng/mL for FAK phosphorylation inhibition in mice).

2. Application in Cellular Assays

• FAK/Pyk2 Signaling Assays: Treat cells with PF-562271 HCl for 1–24 hours to assess rapid phosphorylation changes or long-term effects on cell behavior. Use western blot or ELISA to quantify FAK Tyr397 phosphorylation and downstream targets.
• Migration and Invasion Studies: Incorporate PF-562271 HCl in transwell migration, wound-healing, or 3D spheroid invasion assays to evaluate the impact of FAK inhibition on tumor cell motility.
• Cell Survival and Apoptosis: Assess anti-survival effects in oncogenic models using MTT, CellTiter-Glo, or flow cytometry-based apoptosis assays. Compare with control groups and/or combinatorial regimens (e.g., with epigenetic or immune checkpoint inhibitors).

3. In Vivo Tumor Models

• Tumor Growth Inhibition: Administer PF-562271 HCl to tumor-bearing mice (e.g., melanoma, breast, or prostate cancer models) according to published dosing regimens. Monitor tumor size, metastatic spread, and collect tissue for FAK phosphorylation analysis.
• Tumor Microenvironment Modulation: Investigate changes in immune cell infiltration, cytokine profiles, and stromal composition, as FAK/Pyk2 inhibition is known to impact the tumor immune landscape and pre-metastatic niche formation (see this discussion).

Advanced Applications and Comparative Advantages

Beyond the Bench: Translational Oncology and Immunotherapy Synergy

The unique selectivity profile of PF-562271 HCl enables researchers to interrogate FAK/Pyk2 signaling with minimal off-target effects. This has propelled its use in advanced cancer research, from dissecting metastatic mechanisms to supporting the development of combination therapies.

For example, PF-562271 HCl has been shown to suppress tumor growth and metastasis by inhibiting FAK phosphorylation in vivo. These effects extend to modulation of the tumor microenvironment, including reduction of cancer-associated macrophages and alteration of immune infiltration patterns. This aligns with recent research emphasizing the interplay between kinase signaling and the immune response in cancer—such as the study by Anichini et al. (2022), which highlights the value of targeting signaling pathways to induce favorable immune-related signatures in melanoma and other solid tumors.

Compared to broader-spectrum kinase inhibitors, the reversible and nanomolar-potency profile of PF-562271 HCl ensures robust pathway suppression with reduced off-target toxicity—ideal for translational workflows and in vivo studies targeting tumor growth inhibition and immune modulation.

Interlinking the Literature: Complementary and Contrasting Insights

• The article "PF-562271 HCl: Strategic Dissection of FAK/Pyk2 Signaling..." complements this workflow-focused overview by delving into mechanistic underpinnings and translational strategy, particularly in metastatic prostate cancer.
• For a comparative perspective on immunotherapy synergy, "PF-562271 HCl: Unraveling FAK/Pyk2 Inhibition in Cancer I..." extends the discussion to the interface between kinase inhibition and next-generation immunotherapies, bridging basic research with clinical innovation.
• Meanwhile, "PF-562271 HCl: Advanced FAK/Pyk2 Inhibition for Cancer Re..." provides data-driven insights on selectivity benchmarks and best practices for experimental design, reinforcing the value of PF-562271 HCl in precision oncology workflows.

Troubleshooting, Optimization, and Performance Tips

• Compound Solubility: Ensure complete dissolution in DMSO; avoid water or ethanol. Warming gently (up to 37°C) is recommended for stocks ≥10 mM.
• Stability: PF-562271 HCl is stable as a solid at -20°C. Use freshly prepared solutions for each experiment—prolonged storage in solution may reduce potency.
• Assay Timing: For acute signaling studies, short exposures (30 min–2 h) are optimal. For migration and invasion assays, pre-treat for 4–24 hours to capture phenotypic changes.
• Controls: Include DMSO-only controls to account for vehicle effects. When evaluating combinatorial regimens (e.g., with epigenetic inhibitors such as guadecitabine, as suggested by Anichini et al.), use appropriate single-agent and combination controls.
• Off-Target Considerations: While PF-562271 HCl is highly selective, some CDKs may be affected at higher concentrations—titrate carefully and confirm target engagement via phosphorylation assays.

Future Outlook: PF-562271 HCl in Emerging Cancer Research Paradigms

The future of PF-562271 HCl lies in its integration with cutting-edge cancer research, including:

• Combinatorial Immunotherapy: Building on findings by Anichini et al., combining FAK/Pyk2 inhibition with epigenetic modulators or immune checkpoint blockade may unlock new therapeutic synergies—particularly in resistant solid tumors.
• Tumor Microenvironment Modulation: Advanced studies are leveraging PF-562271 HCl to dissect the interplay between focal adhesion kinase signaling and immune cell recruitment, stromal remodeling, and pre-metastatic niche formation.
• Biomarker Discovery: Quantitative measures of FAK phosphorylation inhibition (e.g., EC₅₀ = 93 ng/mL in mouse models) and downstream gene expression signatures are paving the way for companion diagnostics and patient stratification strategies.

As the oncology field advances toward more precise, mechanism-driven therapies, tools like PF-562271 HCl—available from APExBIO—will remain at the forefront of both fundamental research and translational innovation. For detailed specifications and ordering information, visit the PF-562271 HCl product page.